GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Revenio Group Oyj (OTCPK:REVXF) » Definitions » Research & Development

Revenio Group Oyj (Revenio Group Oyj) Research & Development : $0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Revenio Group Oyj Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Revenio Group Oyj's Research & Development for the three months ended in Mar. 2024 was $0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $0.0 Mil.


Revenio Group Oyj Research & Development Historical Data

The historical data trend for Revenio Group Oyj's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revenio Group Oyj Research & Development Chart

Revenio Group Oyj Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.75 2.15 2.91 3.39 3.11

Revenio Group Oyj Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Revenio Group Oyj Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revenio Group Oyj  (OTCPK:REVXF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Revenio Group Oyj Research & Development Related Terms

Thank you for viewing the detailed overview of Revenio Group Oyj's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Revenio Group Oyj (Revenio Group Oyj) Business Description

Traded in Other Exchanges
Address
Ayritie 22, Vantaa, FIN, 01510
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective and easy-to-use health tech-related screening devices for the detection of diseases of significance to public health. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), perimeter and fundus imaging devices under the iCare brand. Its eye care software platform Oculo offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company's geographical segments include Finland, Other Europe, and Others.

Revenio Group Oyj (Revenio Group Oyj) Headlines

From GuruFocus

Q4 2023 Revenio Group Oyj Earnings Call Transcript

By GuruFocus Research 02-28-2024